Sangamo partners with Pfizer to develop gene therapy for ALS – Reuters
Reuters |
Sangamo partners with Pfizer to develop gene therapy for ALS
Reuters The agency last month approved Spark Therapeutics Inc's treatment for a rare form of blindness, marking the first approval of a gene therapy for an inherited disease. Under the terms of the deal, Sangamo will receive a $12 million upfront payment from … Sangamo, Pfizer Collaborate On Zinc Finger Protein Gene Therapy For ALS Sangamo teams up with Pfizer to develop gene therapy to treat ALS; shares ahead 4% premarket Sangamo, Pfizer to Develop Gene Therapy for Neurodegenerative Disorders |
